Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2025-12-24 @ 10:32 PM
NCT ID:
NCT05757635
Eligibility Criteria:
Inclusion Criteria:
1. First clinical onset or previous cerebral infarction without serious sequela (mRS is 0-2 points)
2. Age ≥ 18 years old
3. Patients or family members own and use smart phones
4. Informed consent signed by the patient or his/her legal representative
Exclusion Criteria:
1. Cranial CT confirmed intracranial hemorrhagic diseases (cerebral hemorrhage, subarachnoid hemorrhage) or malignant space occupying lesions
2. Transient ischemic attack, or stroke mimic
3. Cerebral embolism or suspected cerebral embolism, or other clear anticoagulant indications (such as DVT)
4. Severe disturbance of consciousness: GCS≤8
5. Dysphagia; or gastrointestinal disease or gastrointestinal surgery may affect gastrointestinal absorption
6. After the onset of thrombolysis, stent surgery, or will carry out arteriovenous thrombolysis, interventional or stent surgery patients
7. Angioplasty or other operations that need to suspend antiplatelet drugs may be performed in the last 3 months
8. Patients with severe heart, lung and kidney dysfunction (creatinine \> 2.0 mg/dL or 177 /μ mol/L), severe liver damage (alanine aminotransferase/aspartate transaminas，ALT/AST\>1.5×ULN), malignant tumor, etc., with life expectancy less than 3 months
9. Patients with hemorrhagic tendency, laboratory examination: international normalized ratio （INR）\> 1.5 or activated partial thromboplastin time（APTT） \> 2 times or platelet （PLT ）\< 100×10\^9 / L
10. Patients with previous allergy or intolerance to clopidogrel and aspirin
11. Pregnant or lactating women
12. Patients who could not be followed up as required during the study period
13. Without pariticipation in other intervention clinical studies in the last three months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05757635
Study Brief:
Protocol Section:
NCT05757635